AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
55.16
-0.54 (-0.97%)
At close: Sep 10, 2026, 4:00 PM EDT
54.39
-0.77 (-1.40%)
After-hours: Sep 10, 2026, 5:36 PM EDT
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or -23.53% compared to the previous year.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$2,234,500
Profits / Employee
-$257,567
Market Cap
1.63B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 104 | -32 | -23.53% | 104 | 0 |
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Ascentage Pharma Group International | 828 |
| Novavax | 749 |
| Syndax Pharmaceuticals | 298 |
| Septerna | 123 |
| Inhibrx Biosciences | 110 |
| Tyra Biosciences | 87 |
| Apnimed | 65 |
ANAB News
- 9 days ago - Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 16 days ago - AnaptysBio price target lowered to $70 from $75 at TD Cowen - TheFly
- 1 month ago - AnaptysBio falls -10.8% - TheFly
- 2 months ago - AnaptysBio Proxy statement: Proxy filing - Filings
- 2 months ago - AnaptysBio Proxy statement: Proxy filing - Filings
- 3 months ago - AnaptysBio assumed with a Buy at H.C. Wainwright - TheFly
- 3 months ago - AnaptysBio price target raised to $90 from $85 at Leerink - TheFly
- 4 months ago - AnaptysBio price target raised to $76 from $60 at UBS - TheFly